NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
Advertisement
NewsRx | Free Trials
Advertisement
----------
------------
NewsRx on Facebook
-----
Press Release Submissions
PR Login
*
*

Cancer Weekly


Studies from University of Arizona have provided new information about serous carcinoma



*
Cancer Weekly Library
Library Home

This article was published in Cancer Weekly, which you can subscribe to online.

NewsRx
NewsRx
2009 JUL 14 - (NewsRx.com) -- "Alteration of p53 is an early event in the development of endometrial serous carcinoma (ESC). We have recently identified a group of benign-looking endometria with p53 overexpression, designated ''p53 signatures.'' In this study, we investigated these p53 signatures and evaluated whether they represented ''latent'' precancers for ESC," scientists in the United States report.

"The p53 signatures were specifically associated with ESC, frequently found in the benign-appearing endometrium adjacent to the ESC and only rarely in either the endometrium adjacent to endometrioid carcinomas or in non-cancerous uteri. Forty-two percent of the p53 signature samples showed at least one p53 gene mutation. There were eight ESC uteri with p53 signatures that revealed p53 gene mutations. In four (50%) of these cases, at least one identical p53 gene mutation was found in the signature glands, precancerous regions, and cancerous areas within the same uterus. We concluded that p53 gene mutations apparently precede the morphological changes in affected endometrial cells. The finding of identical p53 mutations in the p53 signatures, precancerous regions, and ESCs in a subset of the uteri provides further evidence of a probable shared lineage between these lesions and suggests that the epithelia that display these p53 signatures are likely latent ESC precancerous regions," wrote X. Zhang and colleagues, University of Arizona.

The researchers concluded: "These findings underscore the significance of the p53 signature as a target for further research in the early detection and prevention of ESC. (Am J Pathol 2009, 174:2000-2006; DOI:10.2353/ajpath.2009.081085)."

Zhang and colleagues published their study in American Journal of Pathology (Molecular Identification of ''Latent Precancers'' for Endometrial Serous Carcinoma in Benign-Appearing Endometrium. American Journal of Pathology, 2009;174(6):2000-2006).

For more information, contact W.X. Zheng, University of Arizona, Dept. of Pathology, College Medical, 1501 N Campbell Avenue, 5224A, Tucson, AZ 85724, USA.

Publisher contact information for the American Journal of Pathology is: American Society Investigative Pathology, Inc., 9650 Rockville Pike, Bethesda, MD 20814-3993, USA.

Keywords: United States, Tucson, Endometrial Cancer, Endometrial Carcinoma, Genetics, Genomics, Oncology, P53 Gene, Pathology, Serous Cancer, Serous Carcinoma, Women's Health, University of Arizona.

This article was prepared by Cancer Weekly editors from staff and other reports. Copyright 2009, Cancer Weekly via NewsRx.com.

NewsRx Passes
Advertisement
------------------------
Security by Verisign PR Login